Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Kena Swanson and Philip Dormitzer.
Kena Swanson
Connection Strength
0.811
Philip Dormitzer
  1. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021 08; 596(7871):273-275.
    View in: PubMed
    Score: 0.059
  2. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
    View in: PubMed
    Score: 0.059
  3. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med. 2021 07 29; 385(5):472-474.
    View in: PubMed
    Score: 0.059
  4. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. NPJ Vaccines. 2021 Mar 25; 6(1):44.
    View in: PubMed
    Score: 0.059
  5. Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. 2021 04 15; 384(15):1466-1468.
    View in: PubMed
    Score: 0.058
  6. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021 04; 27(4):620-621.
    View in: PubMed
    Score: 0.058
  7. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 04; 592(7853):283-289.
    View in: PubMed
    Score: 0.058
  8. Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2021 Feb; 590(7844):E17.
    View in: PubMed
    Score: 0.058
  9. Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2021 Feb; 590(7844):E26.
    View in: PubMed
    Score: 0.058
  10. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021 03 12; 371(6534):1152-1153.
    View in: PubMed
    Score: 0.058
  11. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 12 31; 383(27):2603-2615.
    View in: PubMed
    Score: 0.057
  12. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 12 17; 383(25):2439-2450.
    View in: PubMed
    Score: 0.057
  13. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 10; 586(7830):594-599.
    View in: PubMed
    Score: 0.057
  14. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.